Translational PerspectivesPharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
Under a Creative Commons license
open access
Corresponding Author
Key Words
drug labeling
pharmacogenomics
precision medicine
regulatory perspective
warfarin
Cited by (0)
The authors have reported that they have no relationships relevant to the contents of this paper to disclose. The paper reflects the views of the authors and should not be construed to represent the views or policies of the U.S. Food and Drug Administration.
All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.
© 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.